Portage announces relaunch of adenosine subsidiary as independently managed

Portage Biotech (PRTG) announced the re-launch of its wholly-owned subsidiary as an independently managed company focused on developing best-in-class adenosine receptor antagonists. Peter Molloy has been appointed CEO of the subsidiary, to be named Cyncado Therapeutics. Molloy will lead efforts to secure external financing directly into Cyncado and to advance the clinical development of its portfolio of A2a and A2b receptor antagonists.